Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)

NCT01864265 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.

NCT NCT01864265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01864265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)
Lead sponsor
University of Erlangen-Nürnberg Medical School
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2013
Completion date
January 10, 2020
Enrollment
156 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis